Identification of tumor-borne mediators of pancreatic cancer-associated cachexia
Cancer cachexia describes a multi-factorial disease condition characterized by progressive loss of adipose tissue and skeletal muscle mass. Cachexia is particularly frequent in pancreatic ductal adenocarcinoma (PDAC) and is associated with decreased quality of life, more progressive disease, increased toxicity of cancer treatment and reduced survival. Despite its clinical importance, effective and routine therapeutic measures to counteract wasting are still lacking. Although the significance of cachectic metabolism as a response to tumor and/or host-derived mediators is increasingly recognized, the etiology of cancer cachexia at the molecular level is poorly understood.
We aim to identify and functionally characterize tumor-borne mediators ("cachexokines") of PDAC-associated cachexia. Based on amino acid labeling and mass-spectrometry, we defined a signature of proteins differentially secreted between cachexia-inducing and non-inducing carcinoma cells. By functional in vitro assays, we defined a subset of secreted factors contributing to muscle fiber atrophy and induced adipocyte lipolysis, representing central components cancer-induced wasting. Importantly, these “cachexokines” were also strongly secreted from murine and human pancreatic cancer cell lines as well as markedly increased in serum samples form cachectic pancreatic tumor-bearing mice. Strikingly, in a pilot cohort study, we found significantly elevated cachexokine levels in serum samples from PDAC patients characterized by body weight loss as compared to weight-stable patient samples.
By using in vitro and murine in vivo models, we aim to functionally characterize the identified cachexokines in order to elucidate specific molecular mechanisms of muscle and adipose tissue wasting as well as systemic catabolism. In addition, we will analyze the secretome from PDAC cell lines to define their relevance across cancer entities as well as potentially reveal additional PDAC-specific cachexia mediators. Finally, we will assess the predictive and diagnostic value of selected cachexokines in serum samples from PDAC patients and test their potential to serve as novel intervention points in combinatorial cancer/anti-cachexia therapy.
Obesity and cancer-extracellular matrix, angiogenesis, and adrenergic signaling as unusual suspects linking the two diseases
Pellegata, N. S., Diaz, M. B., Rohm, M., and Herzig, S. (2022). Cancer Metastasis Rev 41, 517-547. doi: 10.1007/s10555-022-10058-y
Geppert, J., Walth, A. A., Terron Exposito, R., Kaltenecker, D., Morigny, P., Machado, J., Becker, M., Simoes, E., Lima, J., Daniel, C., Berriel Diaz, M., Herzig, S., Seelaender, M., and Rohm, M. (2021). Cancers (Basel) 14. doi: 10.3390/cancers14010090
Association of circulating PLA2G7 levels with cancer cachexia and assessment of darapladib as a therapy
Morigny, P., Kaltenecker, D., Zuber, J., Machado, J., Mehr, L., Tsokanos, F. F., Kuzi, H., Hermann, C. D., Voelkl, M., Monogarov, G., Springfeld, C., Laurent, V., Engelmann, B., Friess, H., Zornig, I., Kruger, A., Krijgsveld, J., Prokopchuk, O., Schmidt, S. F., Rohm, M., Herzig, S., and Berriel Diaz, M. (2021). J Cachexia Sarcopenia Muscle 12, 1333-1351. doi: 10.1002/jcsm.12758
Combination therapies induce cancer cell death through the integrated stress response and disturbed pyrimidine metabolism
Hartleben, G., Schorpp, K., Kwon, Y., Betz, B., Tsokanos, F. F., Dantes, Z., Schafer, A., Rothenaigner, I., Monroy Kuhn, J. M., Morigny, P., Mehr, L., Lin, S., Seitz, S., Tokarz, J., Artati, A., Adamsky, J., Plettenburg, O., Lutter, D., Irmler, M., Beckers, J., Reichert, M., Hadian, K., Zeigerer, A., Herzig, S., and Berriel Diaz, M. (2021). EMBO Mol Med 13, e12461. doi: 10.15252/emmm.202012461
Morigny, P., Zuber, J., Haid, M., Kaltenecker, D., Riols, F., Lima, J. D. C., Simoes, E., Otoch, J. P., Schmidt, S. F., Herzig, S., Adamski, J., Seelaender, M., Berriel Diaz, M., and Rohm, M. (2020). J Cachexia Sarcopenia Muscle 11, 1459-1475. doi: 10.1002/jcsm.12626
Molocea, C. E., Tsokanos, F. F., and Herzig, S. (2020). Curr Opin Pharmacol 53, 101-116. doi: 10.1016/j.coph.2020.07.006
Seitz, S., Kwon, Y., Hartleben, G., Julg, J., Sekar, R., Krahmer, N., Najafi, B., Loft, A., Gancheva, S., Stemmer, K., Feuchtinger, A., Hrabe de Angelis, M., Muller, T. D., Mann, M., Bluher, M., Roden, M., Berriel Diaz, M., Behrends, C., Gilleron, J., Herzig, S., and Zeigerer, A. (2019). Nat Metab 1, 1009-1026. doi: 10.1038/s42255-019-0124-x
Levels of the Autophagy-Related 5 Protein Affect Progression and Metastasis of Pancreatic Tumors in Mice
Gorgulu, K., Diakopoulos, K. N., Ai, J., Schoeps, B., Kabacaoglu, D., Karpathaki, A. F., Ciecielski, K. J., Kaya-Aksoy, E., Ruess, D. A., Berninger, A., Kowalska, M., Stevanovic, M., Wormann, S. M., Wartmann, T., Zhao, Y., Halangk, W., Voronina, S., Tepikin, A., Schlitter, A. M., Steiger, K., Artati, A., Adamski, J., Aichler, M., Walch, A., Jastroch, M., Hartleben, G., Mantzoros, C. S., Weichert, W., Schmid, R. M., Herzig, S., Kruger, A., Sainz, B., Jr., Lesina, M., and Algul, H. (2019). Gastroenterology 156, 203-217 e220. doi: 10.1053/j.gastro.2018.09.053
Schmidt, S. F., Rohm, M., Herzig, S., and Berriel Diaz, M. (2018). Trends Cancer 4, 849-860. doi: 10.1016/j.trecan.2018.10.001
Acetyl-CoA Carboxylase 1-Dependent Protein Acetylation Controls Breast Cancer Metastasis and Recurrence
Rios Garcia, M., Steinbauer, B., Srivastava, K., Singhal, M., Mattijssen, F., Maida, A., Christian, S., Hess-Stumpp, H., Augustin, H. G., Muller-Decker, K., Nawroth, P. P., Herzig, S., and Berriel Diaz, M. (2017). Cell Metab 26, 842-855 e845. doi: 10.1016/j.cmet.2017.09.018